Replies to post #4674 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>I would refer you to the Kybersept study which shows that AT3 failed in its clinical trial and showed an additional risk of hemorrhage<

For what it’s worth, I give the ATryn program in DIC/sepsis program a 70% chance of success. The scientific rationale is laid out in several posts in the ReadMeFirst, which includes analysis of the Kybersept study.

--
Most readers here are wise to your agenda, IMO. True, you were able to fool the more gullible posters (e.g. quantumdot), but most of us saw through your game rather quickly.

Out.